Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

non-metastatic prostate cancer

FDA smartphone regulation could stifle innovation

US House Republicans issue warning on guidance and call for more information

- PMLiVE

Former Pfizer VP James Taylor joins INC Research

He was previously VP global clinical trial management at the US pharma firm

- PMLiVE

Pfizer drops hepatitis C candidate filibuvir

Compound was lagging behind investigational drugs from Gilead and AbbVie

- PMLiVE

Pfizer sues as Celebrex patent is reissued in US

Court extends exclusivity of osteoarthritis treatment by 18 months

- PMLiVE

NICE recommends BMS-Pfizer’s Eliquis to prevent stroke

Joins Xarelto and Pradaxa anticoagulants as potential warfarin replacement

- PMLiVE

Second approval in US for Bayer-Onyx’ Stivarga

FDA clears drug to treat patients with gastrointestinal stromal tumours

Roche - Basel

Roche’s Herceptin follow-up cleared in US

FDA approval for Kadcyla (formerly T-DM1) in breast cancer

Product updates from Japan

New approvals and filings include drugs from Takeda, Otsuka, Chugai and Astellas

Search appears on FDA’s radar once again

Warning letter to Florida company puts new slant on regulator's digital focus

- PMLiVE

GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination

Sanofi reception

FDA to review Sanofi’s lixisenatide for diabetes

Follows drug's European approval under brand name Lyxumia earlier this month

- PMLiVE

Channel strategy in pharma

Channel strategy could be a significant 'stone unturned' in the battle to win customers and patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links